Chemed (CHE) Competitors

Chemed (NYSE:CHE) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Does the media refer more to CHE or MEDP?

In the previous week, Medpace had 13 more articles in the media than Chemed. MarketBeat recorded 19 mentions for Medpace and 6 mentions for Chemed. Chemed's average media sentiment score of 1.58 beat Medpace's score of 0.97 indicating that Chemed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Medpace	13 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in CHE or MEDP?

95.9% of Chemed shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 20.3% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has higher earnings and valuation, CHE or MEDP?

Medpace has lower revenue, but higher earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.43B	2.64	$302M	$19.45	22.63
Medpace	$2.11B	7.03	$404.39M	$13.45	39.26

Is CHE or MEDP more profitable?

Medpace has a net margin of 18.74% compared to Chemed's net margin of 11.56%. Medpace's return on equity of 67.66% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	11.56%	25.83%	17.77%
Medpace	18.74%	67.66%	21.86%

Which has more volatility and risk, CHE or MEDP?

Chemed has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Do analysts prefer CHE or MEDP?

Chemed presently has a consensus target price of $578.50, indicating a potential upside of 31.45%. Medpace has a consensus target price of $430.60, indicating a potential downside of 18.46%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Medpace	3 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.94

Summary

Medpace beats Chemed on 9 of the 16 factors compared between the two stocks.